Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 548i-3 is a primate-specific, short non-coding RNA that belongs to the large and diverse mir-548 gene family, which is derived from Made1 miniature inverted-repeat transposable elements (MITEs). MIR548I3 is transcribed as part of a longer primary transcript, then processed by Drosha and Dicer enzymes to generate a mature microRNA incorporated into an RNA-induced silencing complex (RISC), which mediates gene silencing primarily by translational repression or degradation of target mRNAs. The mir-548 family, including 548i-3, is characterized by significant sequence divergence and low conservation, is mainly found in primate genomes, and plays roles in regulating diverse cellular pathways. Bioinformatic analyses indicate family-wide involvement in signaling pathways and cancer, but specific biological or pathological roles for MIR548I3 remain mostly uncharacterized. Expansive target prediction approaches suggest possible involvement in cancer-related regulation, but no therapeutic interventions or drugs specifically target MIR548I3.
Not applicable (no drugs specifically target this microRNA; microRNAs act via base-pairing and regulation of target mRNAs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 548i-3 (MIR548I3).